FluoGuide Future Growth

Future criteria checks 3/6

FluoGuide is forecast to grow earnings and revenue by 55.1% and 162.4% per annum respectively. EPS is expected to grow by 63.4% per annum. Return on equity is forecast to be -9.6% in 3 years.

Key information

55.1%

Earnings growth rate

63.4%

EPS growth rate

Biotechs earnings growth	44.6%
Revenue growth rate	162.4%
Future return on equity	-9.6%
Analyst coverage	Low
Last updated	29 Aug 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

OM:FLUO - Analysts future estimates and past financials data (DKK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	104	33	33	33	1
12/31/2025	N/A	-72	-72	-72	1
12/31/2024	N/A	-35	-35	-35	1
9/30/2024	1	-33	-34	-33	N/A
6/30/2024	1	-36	-34	-34	N/A
3/31/2024	0	-36	-34	-33	N/A
12/31/2023	0	-38	-32	-32	N/A
9/30/2023	0	-37	-32	-32	N/A
6/30/2023	0	-34	-31	-31	N/A
3/31/2023	3	-33	-33	-33	N/A
12/31/2022	7	-27	-38	-38	N/A
9/30/2022	8	-25	-33	-33	N/A
6/30/2022	10	-26	-28	-28	N/A
3/31/2022	13	-24	-22	-22	N/A
12/31/2021	10	-24	-15	-15	N/A
9/30/2021	8	-22	-21	-21	N/A
6/30/2021	6	-17	-24	-24	N/A
3/31/2021	N/A	-18	-13	-13	N/A
12/31/2020	N/A	-17	-9	-9	N/A
9/30/2020	N/A	-14	-9	-8	N/A
6/30/2020	N/A	-16	-5	-5	N/A
3/31/2020	N/A	-12	-13	-13	N/A
12/31/2019	N/A	-10	-11	-11	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FLUO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).

Earnings vs Market: FLUO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: FLUO is expected to become profitable in the next 3 years.

Revenue vs Market: FLUO is forecast to have no revenue next year.

High Growth Revenue: FLUO is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: FLUO is forecast to be unprofitable in 3 years.

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 05:34
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

FluoGuide A/S is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Christian Binder	Redeye

FluoGuide Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

No longer forecast to breakeven

Recent updates

FluoGuide A/S to Report Q3, 2025 Results on Nov 27, 2025

FluoGuide A/S Announces Publication of Positive Phase II Clinical Data for FG001 in Patients with Head and Neck Cancer

Fluoguide A/S Announces Roger Gunnarsson Resigns as Board Member

FluoGuide A/S Submits Clinical Trial Application for Phase II Trial in Head and Neck Cancer

New major risk - Financial position

Fluoguide A/S Announces Executive Changes

FluoGuide A/S to Report Fiscal Year 2024 Final Results on Feb 27, 2025

Less than half of directors are independent

Less than half of directors are independent

FluoGuide A/S Approves Board Changes

New major risk - Revenue and earnings growth

No longer forecast to breakeven

FluoGuide A/S to Report Q2, 2024 Results on Aug 29, 2024

New minor risk - Share price stability

FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001

New minor risk - Shareholder dilution

FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer

FluoGuide A/S Confirms Positive Topline Results from Phase IIa Trial of FG001 in Head & Neck Cancer at International Academy of Oral Oncology Conference

Pfluoguide A/S Provides Positive Interim Data from Phase Lla Trial of Fg001 in Head & Neck Cancer Presented as A Case Report At the World Molecular Imaging Congress in Prague

New minor risk - Profitability

Fluoguide A/S Announces Completion of Patient Enrollment and Treatment in the Phase IIb Trial with Fg001 in Patients with Aggressive Brain Cancer

FluoGuide A/S Announces Positive Interim Results from Phase IIa Trial of FG001 in Head & Neck Cancer

Fluoguide A/S Announces Positive Topline Results from Phase Iia Trial of Fg001 in Lung Cancer

FluoGuide A/S to Report Q3, 2023 Results on Nov 29, 2023

FluoGuide A/S Appoints Ole Larsen as Chief Financial Officer

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

FluoGuide A/S Releases Positive Interim Result of FG001 in Head and Neck Cancer

FluoGuide A/S, Annual General Meeting, Mar 21, 2023

FluoGuide A/S to Report Fiscal Year 2022 Results on Feb 28, 2023

FluoGuide A/S Enrolls First Patient in the Phase IIa Trial in Head and Neck Cancer

FluoGuide A/S Reaches Milestone with FG001 for Phase III Clinical Supply

FluoGuide A/S Releases Positive Interim Result of FG001-CT002

FluoGuide A/S Enrolls the First Patient in the Phase IIb Trial in Aggressive Brain Cancer

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

FluoGuide A/S Presents the Outstanding Clinical Data from the Completed Phase I/IIa Trial with FG001 in Patients with Aggressive Brain Cancer Undergoing Surgery, At the World Molecular Imaging Congress

FluoGuide A/S Ordinary Shares to Be Deleted from OTC Equity

FluoGuide A/S Receives Approval from the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Head and Neck Cancer

FluoGuide Announces CFO Changes

FluoGuide Receives Permission to Start Phase IIb Trial in Aggressive Brain Cancer

Fluoguide A/S Update on Fg001's Clinical Development

FluoGuide Submits a Clinical Trial Application (CTA) to the Danish Medicines Agency to Initiate Phase II Trial with FG001 in Head and Neck Cancer

FluoGuide Publish the Presentation of FG001 Results from the First Clinical Trial in Aggressive Brain Cancer

We're Hopeful That FluoGuide (STO:FLUO) Will Use Its Cash Wisely

FluoGuide A/S Announces Positive Top Line Result from Ongoing Clinical Phase I/II Trial

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

FluoGuide Submits Clinical Trial Application to the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Lung Cancer

Fluoguide Proceeds to Seventh Dose Level with Fg001 in the Ongoing Clinical Phase I/II Trial Following Continued Improvement of Tumor Illumination with Increasing Doses

FluoGuide Announces Regulatory Approval from Swedish Authorities to Commence Phase II Clinical Trial with FG001 in Guiding Surgery of High Grade Glioma in Sweden

FluoGuide A/S Announces Publication of Promising Preclinical Data on FG001 Effect in Treatment of Cancer

FluoGuide A/S Announces Promising Preclinical Data with Fg002 Technology in Guiding Surgical Removal of Cancer

FluoGuide has Received Green Light to Proceed to the Next Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients Undergoing Surgical Treatment of High Grade Glioma

FluoGuide Receives Approval to Commence with FG001 in Evening Dosing in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma

FluoGuide A/S Acquires Rights to Photothermal Therapy Using FG001

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

Dose Escalation Committee Approves FluoGuide A/S's Initiation of the Fourth Dose Level in the Ongoing Clinical Phase I/II Trial Evaluating Safety and Efficacy of Fg001 in Patients with High Grade Glioma Undergoing Neurosurgery

Chairman Arne Ferstad has left the company

Fluoguide A/S Announces Management Changes At the Annual General Meeting Held on February 9, 2021

Fluoguide A/S Announces Publication of Two Patent Applications Covering the Company's uPAR Technology Platform for Improving Surgery

FluoGuide A/S to Report Nine Months, 2021 Results on Nov 24, 2021

New 90-day high: kr.132

FluoGuide A/S Gets Green Light to Proceed to Second Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma

New 90-day low: kr.46.20

FluoGuide A/S Announces First Patient Enrolled in the Phase I/II Clinical Trial Testing FG001 in Patients with High Grade Glioma

FluoGuide Appoints Henrik Moltke as Chief Financial Officer, Effective December 2020

New 90-day high - kr.40.00